Effect of cyclosporine and simulect mono and combination therapy on cardiac allo-transplantation in rats.
- Author:
Hai-Bo XIONG
1
;
Sui-Sheng XIA
;
Zu-Fal HUANG
;
Qi-Fa YE
;
Hao WEN
Author Information
1. Institute of Transplantation, Third Xiangya Hospital, Central South University, Changsha, China. haiboxiong@hotmail.com
- Publication Type:Journal Article
- MeSH:
Animals;
Antibodies, Monoclonal;
pharmacology;
therapeutic use;
Basiliximab;
Combined Modality Therapy;
Cyclosporine;
pharmacology;
therapeutic use;
Female;
Graft Rejection;
immunology;
Heart Transplantation;
adverse effects;
Immunosuppressive Agents;
pharmacology;
therapeutic use;
Rats;
Rats, Sprague-Dawley;
Rats, Wistar;
Recombinant Fusion Proteins;
pharmacology;
therapeutic use
- From:
Journal of Central South University(Medical Sciences)
2005;30(5):549-552
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the effect of cyclosporine and simulect mono or combination therapy on cardiac allo-transplantation in rats.
METHODS:Recipients with allografts were treated with different doses of cyclosporine and/or simulect after cardiac allo-transplantation. Graft survival time was observed; the histopathological examination of graft tissues was performed; and levels of serum IL-2 and IL-4 were determined.
RESULTS:Mono or combination therapy with cyclosporine and/or simulect increased the survival of cardiac allografts. With the prolongation of survival time of the grafts, the rejection of grafts was moderated. The serum IL-2 level increased in acute rejected grafts; the serum IL-4 level increased evidently in long survival grafts.
CONCLUSION:Cyclosporine and simulect have an effect in the prolongation of cardiac allograft survival in rats, and the combination therapy shows an evident synergistic effect.
